3036231-62-3
3036231-62-3
Chemical Structure
Cyclin A/B RxL-IN-1
- CAS. Nr.: 3036231-62-3
- Formula:C46H63Cl2F4N7O7
- Molecular Weight:972.93
SMILES: CC(C[C@@H]1NC([C@H](CCCCNC(C(C)(NC([C@@H](N(C1=O)C)CC2=CC(Cl)=CC=C2Cl)=O)C)=O)N(C([C@H](C3CC3)NC([C@@H]4C[C@H](CN4C(C5(CC6(C5)CCC6)C(F)(F)F)=O)F)=O)=O)C)=O)C
Biological Activity: Cyclin A/B RxL-IN-1 is a inhibitor targeting the Cyclin A/B RxL interaction at the hydrophobic patch (HP). Cyclin A/B RxL-IN-1 inhibits Cyclin A with an IC50 of 0.12 μM. Cyclin A/B RxL-IN-1 demonstrates antitumor efficacy in mouse cell line-derived xenograft (CDX) models. CDK-IN-19 can be used for the study of E2F-driven cancers such as small-cell lung cancer (SCLC)[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cyclin A/B RxL-IN-1 | Cyclin A/B RxL-IN-1 is a inhibitor targeting the Cyclin A/B RxL interaction at the hydrophobic patch (HP). Cyclin A/B RxL-IN-1 inhibits Cyclin A with an IC50 of 0.12 μM. Cyclin A/B RxL-IN-1 demonstrates antitumor efficacy in mouse cell line-derived xenograft (CDX) models. CDK-IN-19 can be used for the study of E2F-driven cancers such as small-cell lung cancer (SCLC). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
